Brian Cheng
Stock Analyst at JP Morgan
(3.09)
# 2,663
Out of 5,182 analysts
79
Total ratings
45.45%
Success rate
2.07%
Average return
Main Sectors:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Maintains: Overweight | $65 → $91 | $68.68 | +32.50% | 3 | Apr 17, 2026 | |
| ALLO Allogene Therapeutics | Upgrades: Neutral | n/a | $2.31 | - | 6 | Apr 16, 2026 | |
| XNCR Xencor | Downgrades: Neutral | $18 → $13 | $12.98 | +0.15% | 6 | Mar 24, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $95 → $106 | $100.00 | +6.00% | 7 | Mar 19, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $27 | $5.13 | +426.32% | 1 | Mar 4, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $29 | $9.66 | +200.36% | 1 | Mar 2, 2026 | |
| TGTX TG Therapeutics | Maintains: Overweight | $49 → $46 | $36.62 | +25.61% | 1 | Feb 2, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $92 → $122 | $135.30 | -9.83% | 2 | Feb 2, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $70 → $125 | $84.91 | +47.21% | 1 | Dec 10, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.23 | - | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $12 → $5 | $13.63 | -63.32% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $23 | $28.10 | -18.15% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.24 | - | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $3.94 | - | 1 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $33 | $28.58 | +15.47% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $20 | $27.41 | -27.03% | 7 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $48.79 | +43.49% | 1 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.13 | - | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $23.56 | -6.62% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $23.95 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.91 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $9.06 | +264.24% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.50 | +300.00% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $850 → $700 | $4.87 | +14,273.72% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.94 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $320 → $96 | $7.90 | +1,115.19% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.09 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.36 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $8.59 | +889.52% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.94 | +134.90% | 1 | Aug 3, 2021 |
CG Oncology
Apr 17, 2026
Maintains: Overweight
Price Target: $65 → $91
Current: $68.68
Upside: +32.50%
Allogene Therapeutics
Apr 16, 2026
Upgrades: Neutral
Price Target: n/a
Current: $2.31
Upside: -
Xencor
Mar 24, 2026
Downgrades: Neutral
Price Target: $18 → $13
Current: $12.98
Upside: +0.15%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Overweight
Price Target: $95 → $106
Current: $100.00
Upside: +6.00%
Protara Therapeutics
Mar 4, 2026
Initiates: Overweight
Price Target: $27
Current: $5.13
Upside: +426.32%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $29
Current: $9.66
Upside: +200.36%
TG Therapeutics
Feb 2, 2026
Maintains: Overweight
Price Target: $49 → $46
Current: $36.62
Upside: +25.61%
Revolution Medicines
Feb 2, 2026
Maintains: Overweight
Price Target: $92 → $122
Current: $135.30
Upside: -9.83%
Kymera Therapeutics
Dec 10, 2025
Maintains: Overweight
Price Target: $70 → $125
Current: $84.91
Upside: +47.21%
OPKO Health
Nov 20, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Nov 7, 2025
Downgrades: Underweight
Price Target: $12 → $5
Current: $13.63
Upside: -63.32%
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $28.10
Upside: -18.15%
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.24
Upside: -
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.94
Upside: -
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $28.58
Upside: +15.47%
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $27.41
Upside: -27.03%
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $48.79
Upside: +43.49%
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.13
Upside: -
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $23.56
Upside: -6.62%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.95
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.91
Upside: -
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $9.06
Upside: +264.24%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.50
Upside: +300.00%
Sep 25, 2023
Maintains: Overweight
Price Target: $850 → $700
Current: $4.87
Upside: +14,273.72%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.94
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $320 → $96
Current: $7.90
Upside: +1,115.19%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.09
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.36
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $8.59
Upside: +889.52%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.94
Upside: +134.90%